Pfizer Full Year 2025 Financial ReportPfizerPfizer’s 2025 financial results show a 2% decline in revenue, driven by lower COVID-19 product sales. Non-COVID products and a strong R&D pipeline drive growth. The company projects steady performance with key catalysts in 2026.
Novo Nordisk Full Year 2025 Financial ReportNovo NordiskNovo Nordisk's 2025 report highlights strong revenue growth driven by Wegovy? and Ozempic?, despite challenges in profit margins and rising costs. The company focuses on R&D, sustainability, and managing risks like competition and regulatory pressures.
Daiichi Sankyo Full Year 2025 Financial ReportFinancial statementsDaiichi Sankyo's FY2025 Q3 report highlights $4.4 billion in sales for Enhertu (DS-8201) and significant growth in its ADC portfolio. With groundbreaking treatments and strong pipeline advancements, the company is reshaping the oncology landscape.
Novartis Full Year 2025 Financial ReportFinancial statementsNovartis' 2025 financial results show strong growth, driven by innovations like Kisqali, Pluvicto, and Leqvio. With a strong pipeline and key market expansions, the company is well-positioned for future growth despite patent challenges.
Roche Full Year 2025 Financial ReportFinancial statementsRoche's 2025 financial results show a 7% sales growth, driven by innovative drugs and diagnostics. Core operating profit rose 13%, with strong performance across key markets. The company remains optimistic for 2026, focusing on sustainable growth.
Lonza Full Year 2025 Financial ReportLonzaLonza reported $7B in revenue for 2025, with its CDMO business driving 70% of growth. Strategic shifts, expanded capacity, and a focus on next-gen therapies like CGT and ADCs position Lonza for continued success in 2026.
Sanofi Full Year 2025 Financial ReportSanofiSanofi's 2025 results show a 9.9% revenue growth to €43.63 billion, driven by strong sales of Dupixent and new product launches. The company also achieved significant R&D breakthroughs, strategic investments, and continued commitment to sustainability.
Henlius Biotech H1 2025 Financial ReportHenlius BiotechHenlius reports H1 2025 results: overseas profits soar 200%, global product expansion, and innovation pipeline growth, driving ‘Globalization 2.0’ and next-gen therapies worldwide.
Hansoh Pharma H1 2025 Financial ReportHansoh PharmaHansoh Pharma’s 2025 interim report highlights strong growth, innovation-driven transformation, and a robust global pipeline, setting a new benchmark for Chinese biopharma.
Hengrui H1 2025 Financial ReportHengrui PharmaceuticalsHengrui Medicine’s 2025 half-year report shows 60% revenue from innovative drugs and $12B potential overseas deals, highlighting strong growth, R&D depth, and global expansion.
EN
Agricultural News
Food News
Industrial News
Cosmetic News
Pharmaceutical News
Science News
